GRI · Insider Trading
GRI Bio, Inc. Common Stock
Every open-market purchase and sale reported by GRI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-09-22 | Walter Marc Hertz | Chief Executive Officer | A | +103,067 deriv. | — |
| 2025-09-22 | David Charles Baker | Director | A | +23,605 deriv. | — |
| 2025-09-22 | David Leslie Szekeres | Director | A | +39,897 deriv. | — |
| 2025-09-22 | Leanne Kelly | Chief Financial Officer | A | +43,222 deriv. | — |
| 2025-09-22 | Roelof Rongen | Director | A | +23,605 deriv. | — |
| 2025-09-22 | Camilla V Simpson | Director | A | +23,605 deriv. | — |
| 2025-09-22 | Vipin Chaturvedi | Chief Scientific Officer | A | +43,222 deriv. | — |
| 2025-08-27 | Vipin Chaturvedi | Chief Scientific Officer | A | +11,854 deriv. | — |
| 2025-08-27 | David Charles Baker | Director | A | +5,994 deriv. | — |
| 2025-08-27 | Camilla V Simpson | Director | A | +5,994 deriv. | — |
| 2025-08-27 | Roelof Rongen | Director | A | +5,994 deriv. | — |
| 2025-08-27 | Leanne Kelly | Chief Financial Officer | A | +11,854 deriv. | — |
| 2025-08-27 | Walter Marc Hertz | Chief Executive Officer | A | +26,688 deriv. | — |
| 2025-08-27 | David Leslie Szekeres | Director | A | +10,276 deriv. | — |
| 2025-08-14 | David Charles Baker | Director | A | +4,527 deriv. | — |
| 2025-08-14 | David Leslie Szekeres | Director | A | +7,545 deriv. | — |
| 2025-08-14 | Roelof Rongen | Director | A | +4,527 deriv. | — |
| 2025-08-14 | Camilla V Simpson | Director | A | +4,527 deriv. | — |
| 2025-01-24 | Leanne Kelly | Chief Financial Officer | A | +43,319 deriv. | — |
| 2025-01-24 | Roelof Rongen | Director | A | +30,297 deriv. | — |
| 2025-01-24 | David Leslie Szekeres | Director | A | +51,937 deriv. | — |
| 2025-01-24 | David Charles Baker | Director | A | +30,297 deriv. | — |
| 2025-01-24 | Camilla V Simpson | Director | A | +30,297 deriv. | — |
| 2025-01-24 | Walter Marc Hertz | Chief Executive Officer | A | +129,730 deriv. | — |
| 2025-01-24 | Vipin Chaturvedi | Chief Scientific Officer | A | +43,319 deriv. | — |
| 2023-09-26 | Leanne Kelly | Chief Financial Officer | A | +83,333 deriv. | — |
| 2023-08-14 | Roelof Rongen | Director | A | +34,483 deriv. | — |
| 2023-08-14 | David Charles Baker | Director | A | +34,483 deriv. | — |
| 2023-08-14 | Camilla V Simpson | Director | A | +34,483 deriv. | — |
| 2023-08-14 | David Leslie Szekeres | Director | A | +34,483 deriv. | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GRI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.